Detalles de la búsqueda
1.
FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab.
Radiology
; 307(3): e221180, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36853183
2.
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
J Transl Med
; 21(1): 753, 2023 10 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37880788
3.
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Eur J Nucl Med Mol Imaging
; 47(12): 2776-2786, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32338306
4.
In Vitro Experimental Approach for Studying Human Pulmonary Artery Smooth Muscle Cells and Endothelial Cells Proliferation and Migration.
Methods Mol Biol
; 2803: 49-58, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38676884
5.
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
Eur J Cancer
; 196: 113441, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37988842
6.
Increased Thyroidal Activity on Routine FDG-PET/CT after Combination Immune Checkpoint Inhibition: Temporal Associations with Clinical and Biochemical Thyroiditis.
Cancers (Basel)
; 15(24)2023 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38136348
7.
Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis.
Front Endocrinol (Lausanne)
; 14: 1295865, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38093958
8.
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes.
J Immunother Cancer
; 10(6)2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35764368
Resultados
1 -
8
de 8
1
Próxima >
>>